References
- Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 2015;137:581-8. https://doi.org/10.1016/j.ygyno.2015.03.041
- Matsuo K, Ross MS, Machida H, Blake EA, Roman LD. Trends of uterine carcinosarcoma in the United States. J Gynecol Oncol 2018;29:e22. https://doi.org/10.3802/jgo.2018.29.e22
- Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 2017;31:411-23. https://doi.org/10.1016/j.ccell.2017.02.010
- Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, et al. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol 2016;27:1257-66. https://doi.org/10.1093/annonc/mdw161
- Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol 2017;145:78-87.
- Das S, Batra SK. Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy. Cancer Res 2015;75:4669-74. https://doi.org/10.1158/0008-5472.CAN-15-1050
- Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers 2016;2:16061. https://doi.org/10.1038/nrdp.2016.61
- Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 2007;107:513-7. https://doi.org/10.1016/j.ygyno.2007.08.060
- Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, et al. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Int J Clin Oncol 2016;21:168-76. https://doi.org/10.1007/s10147-015-0859-7
- Thomakos N, Rodolakis A, Zagouri F, Zacharakis D, Sotiropoulou M, Akrivos N, et al. Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas? Arch Gynecol Obstet 2013;287:97-102. https://doi.org/10.1007/s00404-012-2529-6
- Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011;17:7164-73. https://doi.org/10.1158/1078-0432.CCR-11-0649
- Matsuo K, Johnson MS, Im DD, Ross MS, Bush SH, Yunokawa M, et al. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. J Surg Oncol 2018;117:488-96. https://doi.org/10.1002/jso.24861
- Salani R, Khanna N, Frimer M, Bristow RE, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146:3-10. https://doi.org/10.1016/j.ygyno.2017.03.022
Cited by
- Uterine carcinosarcoma: a primer for radiologists vol.44, pp.8, 2018, https://doi.org/10.1007/s00261-019-02038-8
- Tumour markers and their utility in imaging of abdominal and pelvic malignancies vol.76, pp.2, 2018, https://doi.org/10.1016/j.crad.2020.07.033